Hepatitis E virus: Infection beyond the liver?

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study  Harry R. Dalton, Jeroen J.J. van Eijk, Pascal.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Hepatic CD141+IFNλ+ DC subset: One against all?
R. Cavallo  Clinical Microbiology and Infection 
Volume 61, Issue 6, Pages (December 2014)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 57, Issue 1, Pages 6-8 (July 2012)
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
J. Ambrosioni, A. Mamin, A. Hadengue, M. Bernimoulin, K. Samii, C
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Immigration and viral hepatitis
Virological tools to diagnose and monitor hepatitis C virus infection
Living donor liver transplantation: is the hype over?
Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Marina Berenguer, Detlef Schuppan  Journal of Hepatology 
Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure”  Rakhi Maiwall,
Autoimmune hepatitis: A life-long disease
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 68, Issue 3, Pages (March 2018)
The role of vaccination in preventing pneumococcal disease in adults
Volume 70, Issue 1, Pages (January 2019)
Acute-on chronic liver failure
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Volume 59, Issue 3, Pages (September 2013)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
EASL Recognition Award Recipient 2017: Prof. Giorgina Mieli-Vergani
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
EASL Clinical Practice Guidelines on hepatitis E virus infection
Sven Pischke, Patrick Behrendt, Michael P Manns, Heiner Wedemeyer 
Volume 63, Issue 2, Pages (August 2015)
Senescence in chronic liver disease: Is the future in aging?
Volume 50, Issue 4, Pages (April 2009)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 393, Issue 10174, Pages (March 2019)
miR-122 – A key factor and therapeutic target in liver disease
Volume 50, Issue 3, Pages (March 2009)
Immigration and viral hepatitis
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Volume 70, Issue 5, Pages (May 2019)
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Hepatitis E virus: Infection beyond the liver? Sven Pischke, Johannes Hartl, Suzan D. Pas, Ansgar W. Lohse, Bart C. Jacobs, Annemiek A. Van der Eijk  Journal of Hepatology  Volume 66, Issue 5, Pages 1082-1095 (May 2017) DOI: 10.1016/j.jhep.2016.11.016 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Reported extrahepatic manifestations of HEV infection. The pathogenesis of these manifestations (A) is unknown but we hypothesize mechanisms with (B) or without (C) virus replication at these extrahepatic sites. Local viral replication may damage the infected cells and tissues directly (B) or may trigger an immune response, especially in cases of neuronal damage (C). For example, in GBS, molecular mimicry between infectious agents and peripheral nerve self-antigens may result in nerve injury, although it is unknown if such mechanisms play a role in HEV-related GBS. Other mechanisms by which an immune response to HEV may trigger extrahepatic damage is via induction of other antibodies, T-cells, deposition of HEV-antigens/antibody-immune-complexes or other mediators of inflammation. Journal of Hepatology 2017 66, 1082-1095DOI: (10.1016/j.jhep.2016.11.016) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 2 In immunocompetent patients, HEV-3 rarely causes symptomatic hepatitis but can result in acute fulminant hepatitis with decompensation in patients with underlying chronic liver disease. HEV GT3 and HEV GT4 may lead to chronic infection in patients with an impaired immune response due to illness or medication. Both acute and chronic HEV infections have been associated with extrahepatic manifestations. Currently no vaccine is available other countries than in China. There are no data to suggest whether such a vaccine would protect against HEV (re)infection in immunocompromised patients. Journal of Hepatology 2017 66, 1082-1095DOI: (10.1016/j.jhep.2016.11.016) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions